523 related articles for article (PubMed ID: 29163490)
1. Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.
Solinas C; Garaud S; De Silva P; Boisson A; Van den Eynden G; de Wind A; Risso P; Rodrigues Vitória J; Richard F; Migliori E; Noël G; Duvillier H; Craciun L; Veys I; Awada A; Detours V; Larsimont D; Piccart-Gebhart M; Willard-Gallo K
Front Immunol; 2017; 8():1412. PubMed ID: 29163490
[TBL] [Abstract][Full Text] [Related]
2. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.
Buisseret L; Garaud S; de Wind A; Van den Eynden G; Boisson A; Solinas C; Gu-Trantien C; Naveaux C; Lodewyckx JN; Duvillier H; Craciun L; Veys I; Larsimont D; Piccart-Gebhart M; Stagg J; Sotiriou C; Willard-Gallo K
Oncoimmunology; 2017; 6(1):e1257452. PubMed ID: 28197375
[TBL] [Abstract][Full Text] [Related]
4. Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.
Liu X; Tsang JYS; Hlaing T; Hu J; Ni YB; Chan SK; Cheung SY; Tse GM
Oncologist; 2017 Nov; 22(11):1316-1324. PubMed ID: 28701569
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
6. BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.
Solinas C; Marcoux D; Garaud S; Vitória JR; Van den Eynden G; de Wind A; De Silva P; Boisson A; Craciun L; Larsimont D; Piccart-Gebhart M; Detours V; t'Kint de Roodenbeke D; Willard-Gallo K
Cancer Lett; 2019 May; 450():88-97. PubMed ID: 30797818
[TBL] [Abstract][Full Text] [Related]
7. Tumor-Infiltrating Lymphocytes (TIL), Tertiary Lymphoid Structures (TLS), and Expression of PD-1, TIM-3, LAG-3 on TIL in Invasive and In Situ Ductal Breast Carcinomas and Their Relationship with Prognostic Factors.
Acar E; Esendağlı G; Yazıcı O; Dursun A
Clin Breast Cancer; 2022 Dec; 22(8):e901-e915. PubMed ID: 36089459
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
9. CD204-positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand-1 expression.
Nagano M; Saito K; Kozuka Y; Ichishi M; Yuasa H; Noro A; Imai N; Shibusawa M; Kimoto M; Ishitobi M; Tono Y; Oda H; Ishihara M; Mizuno T; Ogawa T; Katayama N
Oncol Lett; 2021 Jan; 21(1):36. PubMed ID: 33262828
[TBL] [Abstract][Full Text] [Related]
10. Tumor Infiltrating Lymphocytes (TILS) and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications from Pathologist's Perspective.
Angelico G; Broggi G; Tinnirello G; Puzzo L; Vecchio GM; Salvatorelli L; Memeo L; Santoro A; Farina J; Mulé A; Magro G; Caltabiano R
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760449
[TBL] [Abstract][Full Text] [Related]
11. FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer.
De Silva P; Garaud S; Solinas C; de Wind A; Van den Eyden G; Jose V; Gu-Trantien C; Migliori E; Boisson A; Naveaux C; Duvillier H; Craciun L; Larsimont D; Piccart-Gebhart M; Willard-Gallo K
EBioMedicine; 2019 Jan; 39():226-238. PubMed ID: 30579865
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
13. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.
Loi S; Michiels S; Adams S; Loibl S; Budczies J; Denkert C; Salgado R
Ann Oncol; 2021 Oct; 32(10):1236-1244. PubMed ID: 34311075
[TBL] [Abstract][Full Text] [Related]
14. Single-cell transcriptome sequencing of B-cell heterogeneity and tertiary lymphoid structure predicts breast cancer prognosis and neoadjuvant therapy efficacy.
Wang Q; Sun K; Liu R; Song Y; Lv Y; Bi P; Yang F; Li S; Zhao J; Li X; Chen D; Mei J; Yang R; Chen K; Liu D; Tang S
Clin Transl Med; 2023 Aug; 13(8):e1346. PubMed ID: 37525587
[TBL] [Abstract][Full Text] [Related]
15. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Kassardjian A; Shintaku PI; Moatamed NA
PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral, rather than stromal, CD8+ T cells could be a potential negative prognostic marker in invasive breast cancer patients.
Catacchio I; Silvestris N; Scarpi E; Schirosi L; Scattone A; Mangia A
Transl Oncol; 2019 Mar; 12(3):585-595. PubMed ID: 30682679
[TBL] [Abstract][Full Text] [Related]
17. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
18. Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry.
Park Y; Seo AN; Koh J; Nam SK; Kwak Y; Ahn SH; Park DJ; Kim HH; Lee HS
Oncoimmunology; 2021; 10(1):1954761. PubMed ID: 34367732
[TBL] [Abstract][Full Text] [Related]
19. Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.
Garaud S; Buisseret L; Solinas C; Gu-Trantien C; de Wind A; Van den Eynden G; Naveaux C; Lodewyckx JN; Boisson A; Duvillier H; Craciun L; Ameye L; Veys I; Paesmans M; Larsimont D; Piccart-Gebhart M; Willard-Gallo K
JCI Insight; 2019 Aug; 5(18):. PubMed ID: 31408436
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.
Kakavand H; Wilmott JS; Menzies AM; Vilain R; Haydu LE; Yearley JH; Thompson JF; Kefford RF; Hersey P; Long GV; Scolyer RA
Clin Cancer Res; 2015 Jul; 21(14):3140-8. PubMed ID: 25609064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]